TRACERx Renal CAPTURE Sub-study (TRACERxRenal)
Rare Kidney Cancers / Posted 4 weeks ago
Summary
TRACERx Renal: This is a translational study, which, aims to develop prognostic and predictive biomarkers for patients with renal cell carcinoma (RCC).
CAPTURE Sub-study: Covid-19 antiviral response in a pan-tumour immune monitoring study
-
Inclusion Criteria :
- Age 18- years or older
- Patients with histopathologically confirmed renal cell carcinoma, or suspected renal cell carcinoma, proceeding to neoadjuvant therapy and/or nephrectomy/metastasectomy, or identified as having progressive disease
- Or in patients undergoing nephrectomy for non-malignant disease
- Medical and/or surgical management in accordance with national and/or local guidelines
- Written informed consent
- **CAPTURE sub-study Inclusion criteria:**
- Documented informed consent
- Age 18 years or older
- Confirmed cancer diagnosis (irrespective of cancer type, disease burden or treatment)
- Group A: Suspected infection with SARS-CoV-2 or positive test for SARS-CoV-2
- Group B: no clinical indication to test for SARS-CoV-2 (by current Trust guidelines*) or tested negative for SARS-CoV-2
- Group C: Volunteers without cancer with SARS-CoV-2 (symptomatic and asymptomatic) and those without clinical indication (current national guidelines*) for SARS-CoV-2 testing or tested negative for SARS-CoV-2
-
Exclusion Criteria :
- Any concomitant medical or psychiatric problems which, in the opinion of the investigator, would prevent completion of treatment or follow-up
- Medical or psychological condition that would preclude informed consent
- Lack of adequate tissue
- Study start date : February 5, 2012
- Study end date : September 1, 2023
- Wales-Based Study Contact : Please speak to your clinician
- Principal Investigator : Samra Turajlic (Royal Marsden NHS Foundation Trust)